HALOZYME THERAPEUTICS INC (HALO) Stock Overview
NASDAQ:HALO - US40637H1095 - Common Stock
HALO Key Statistics, Chart & Performance
The current stock price of HALO is 71.61 USD. In the past month the price increased by 21.85%. In the past year, price increased by 14.17%.
HALO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.78 | 370.06B | ||
| AMGN | AMGEN INC | 13.56 | 159.03B | ||
| GILD | GILEAD SCIENCES INC | 15.01 | 144.47B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.46 | 102.07B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.11 | 64.58B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.96B | ||
| ARGX | ARGENX SE - ADR | 71.6 | 40.62B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.79 | 33.98B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.63B | ||
| INSM | INSMED INC | N/A | 25.16B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.69 | 20.39B |
Related stock screener links
About HALO
Company Profile
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Company Info
HALOZYME THERAPEUTICS INC
12390 El Camino Real
San Diego CALIFORNIA 92121-1345 US
CEO: Helen I. Torley
Employees: 350
Phone: 18587948889
HALOZYME THERAPEUTICS INC / HALO FAQ
What is the stock price of HALOZYME THERAPEUTICS INC today?
The current stock price of HALO is 71.61 USD. The price increased by 0.67% in the last trading session.
What is the ticker symbol for HALOZYME THERAPEUTICS INC stock?
The exchange symbol of HALOZYME THERAPEUTICS INC is HALO and it is listed on the Nasdaq exchange.
On which exchange is HALO stock listed?
HALO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HALOZYME THERAPEUTICS INC stock?
16 analysts have analysed HALO and the average price target is 67.96 USD. This implies a price decrease of -5.1% is expected in the next year compared to the current price of 71.61. Check the HALOZYME THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HALOZYME THERAPEUTICS INC worth?
HALOZYME THERAPEUTICS INC (HALO) has a market capitalization of 8.82B USD. This makes HALO a Mid Cap stock.
How many employees does HALOZYME THERAPEUTICS INC have?
HALOZYME THERAPEUTICS INC (HALO) currently has 350 employees.
What are the support and resistance levels for HALOZYME THERAPEUTICS INC (HALO) stock?
HALOZYME THERAPEUTICS INC (HALO) has a support level at 63.44. Check the full technical report for a detailed analysis of HALO support and resistance levels.
Is HALOZYME THERAPEUTICS INC (HALO) expected to grow?
The Revenue of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 24.44% in the next year. Check the estimates tab for more information on the HALO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HALOZYME THERAPEUTICS INC (HALO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HALO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HALO, evaluating the profitability, health, valuation and growth aspects
- HALOZYME THERAPEUTICS INC (HALO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HALOZYME THERAPEUTICS INC (HALO) Sales and EPS estimates to see what analysts future expectations are.
- HALOZYME THERAPEUTICS INC (HALO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HALOZYME THERAPEUTICS INC (HALO) Insider and Institutional Ownership to learn about the owners and their transactions.
- HALOZYME THERAPEUTICS INC (HALO) Stock Chart to make your own analysis
- HALOZYME THERAPEUTICS INC (HALO) Latest news and press-releases to stay up to date.
Does HALOZYME THERAPEUTICS INC (HALO) stock pay dividends?
HALO does not pay a dividend.
When does HALOZYME THERAPEUTICS INC (HALO) report earnings?
HALOZYME THERAPEUTICS INC (HALO) will report earnings on 2025-10-29, after the market close.
What is the Price/Earnings (PE) ratio of HALOZYME THERAPEUTICS INC (HALO)?
The PE ratio for HALOZYME THERAPEUTICS INC (HALO) is 13.82. This is based on the reported non-GAAP earnings per share of 5.18 and the current share price of 71.61 USD. Check the full fundamental report for a full analysis of the valuation metrics for HALO.
What is the Short Interest ratio of HALOZYME THERAPEUTICS INC (HALO) stock?
The outstanding short interest for HALOZYME THERAPEUTICS INC (HALO) is 8.15% of its float. Check the ownership tab for more information on the HALO short interest.
HALO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to HALO. When comparing the yearly performance of all stocks, HALO is one of the better performing stocks in the market, outperforming 84.39% of all stocks.
HALO Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to HALO. Both the health and profitability get an excellent rating, making HALO a very profitable company, without any liquidiy or solvency issues.
HALO Financial Highlights
Over the last trailing twelve months HALO reported a non-GAAP Earnings per Share(EPS) of 5.18. The EPS increased by 58.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 47.28% | ||
| ROA | 27.13% | ||
| ROE | 167.48% | ||
| Debt/Equity | 4.54 |
HALO Forecast & Estimates
16 analysts have analysed HALO and the average price target is 67.96 USD. This implies a price decrease of -5.1% is expected in the next year compared to the current price of 71.61.
For the next year, analysts expect an EPS growth of 32.62% and a revenue growth 24.44% for HALO